Company Description

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies.

It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.

The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Citius Oncology, Inc.

Country	United States
Founded	2021
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
CEO	Leonard Mazur

Contact Details

Address: 11 Commerce Drive, First Floor Cranford, New Jersey 07016 United States
Phone	908 967 6677

Stock Details

Ticker Symbol	CTOR
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	October - September
Reporting Currency	USD
CIK Code	0001851484
CUSIP Number	17331Y109
ISIN Number	US17331Y1091
Employer ID	99-4362660
SIC Code	2834

Key Executives

Name	Position
Leonard L. Mazur	Chief Executive Officer, President and Executive Chairman
Myron Z. Holubiak	Secretary and Executive Vice Chairman
Dr. Myron S. Czuczman M.D.	Executive Vice President and Chief Medical Officer
Jaime Bartushak	Chief Financial Officer and Treasurer

Latest SEC Filings

Date	Type	Title
Mar 4, 2026	8-K	Current Report
Mar 2, 2026	EFFECT	Notice of Effectiveness
Feb 20, 2026	POS AM	Post-Effective amendments for registration statement
Feb 17, 2026	SCHEDULE 13G/A	Filing
Feb 13, 2026	8-K	Current Report
Feb 13, 2026	10-Q	Quarterly Report
Jan 29, 2026	DEF 14C	Filing
Jan 20, 2026	PRE 14C	Filing
Jan 12, 2026	EFFECT	Notice of Effectiveness
Jan 5, 2026	S-3	Registration statement under Securities Act of 1933

View All SEC Filings